Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley Advises EMZ Partners on Its Significant Minority Investment in Steinbach & VollmannJuly 13, 2026Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZenecaJuly 13, 2026Sidley Shortlisted at the FT Innovative Lawyers Awards Europe 2026July 9, 2026Delaware Court of Chancery Draws a Line on Release Conditions in M&AJuly 8, 2026EU Forced Labor Regulation Moves Toward Implementation: How Companies Should PrepareJuly 7, 2026Sidley Represents Clara Vista Investment Partners in Its Acquisition of Majority Stake in Frosinone CalcioJuly 6, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory